Holen Sie sich die Stockscreener-App
143.26
0.94%
1.34
Handel nachbörslich:
143.26
Schlusskurs vom Vortag:
$141.92
Offen:
$142.85
24-Stunden-Volumen:
907.14K
Relative Volume:
0.96
Marktkapitalisierung:
$14.50B
Einnahmen:
$2.24B
Nettoeinkommen (Verlust:
$385.90M
KGV:
38.41
EPS:
3.73
Netto-Cashflow:
$440.10M
1W Leistung:
+1.67%
1M Leistung:
+4.81%
6M Leistung:
-0.96%
1J Leistung:
+4.48%
1-Tages-Spanne:
$141.57
$144.82
1-Wochen-Bereich:
$138.46
$144.82
52-Wochen-Spanne:
$110.95
$157.98
Neurocrine Biosciences Inc Stock (NBIX) Company Profile
Firmenname
Neurocrine Biosciences Inc
Sektor
Telefon
(858) 617-7600
Adresse
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Vergleichen Sie NBIX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NBIX
Neurocrine Biosciences Inc
|
143.26 | 14.50B | 2.24B | 385.90M | 440.10M | 3.73 |
|
ZTS
Zoetis Inc
|
165.89 | 74.84B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.24 | 41.78B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
12.92 | 40.96B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
21.92 | 24.83B | 16.77B | -959.00M | 1.37B | -0.85 |
Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-10 | Fortgesetzt | Raymond James | Outperform |
| 2024-08-29 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2024-04-24 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-12-13 | Fortgesetzt | Citigroup | Neutral |
| 2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-21 | Bestätigt | Mizuho | Neutral |
| 2023-07-24 | Hochstufung | SVB Securities | Market Perform → Outperform |
| 2023-07-06 | Hochstufung | BMO Capital Markets | Underperform → Market Perform |
| 2023-05-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2023-03-30 | Hochstufung | Canaccord Genuity | Hold → Buy |
| 2023-03-03 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-02-03 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-11-14 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-10-11 | Eingeleitet | UBS | Buy |
| 2022-09-26 | Eingeleitet | Wells Fargo | Equal Weight |
| 2022-06-06 | Fortgesetzt | Jefferies | Buy |
| 2022-03-03 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-02-25 | Hochstufung | Goldman | Neutral → Buy |
| 2022-01-18 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Underperform |
| 2021-11-17 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-10-14 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Fortgesetzt | Needham | Hold |
| 2021-08-06 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2021-05-18 | Fortgesetzt | Goldman | Neutral |
| 2021-05-06 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2021-02-02 | Eingeleitet | Raymond James | Outperform |
| 2020-09-30 | Eingeleitet | The Benchmark Company | Hold |
| 2020-08-04 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-06-29 | Herabstufung | Goldman | Buy → Neutral |
| 2020-06-09 | Eingeleitet | Wedbush | Outperform |
| 2020-03-06 | Eingeleitet | Citigroup | Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-02-24 | Eingeleitet | William Blair | Outperform |
| 2020-02-06 | Eingeleitet | Mizuho | Neutral |
| 2020-02-05 | Bestätigt | H.C. Wainwright | Buy |
| 2019-12-13 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-08-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2019-07-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-06-05 | Eingeleitet | Guggenheim | Neutral |
| 2019-05-21 | Eingeleitet | Credit Suisse | Outperform |
| 2019-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-04-12 | Eingeleitet | Evercore ISI | Outperform |
| 2019-02-06 | Bestätigt | BofA/Merrill | Buy |
| 2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2018-12-13 | Eingeleitet | Goldman | Buy |
| 2018-11-21 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Neurocrine Biosciences Inc Aktie (NBIX) Neueste Nachrichten
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock - MSN
Neurocrine Bio stock retains outperform rating on robust pipeline - MSN
Avanza Fonder AB Invests $1.80 Million in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Kyle Gano Sells 65,000 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine Biosciences CEO Gano Kyle sells $9.2 million in stock By Investing.com - Investing.com UK
How To Trade (NBIX) - Stock Traders Daily
Endometriosis Pipeline 2024: Detailed Clinical Trials - openPR
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Shares Sold by Burney Co. - MarketBeat
Neurocrine Sues to Clear New Drug of Spruce's Patent 'Ransom' - Bloomberg Law
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives $164.81 Consensus PT from Brokerages - MarketBeat
40 Under 40: Ashley Allan, Neurocrine Biosciences - MM+M Online
Nxera Pharma Provides Update on Neurocrine's Progress with its Partnered Muscarinic Agonist Portfolio - The Manila Times
Nxera Pharma Provides Update on Neurocrine’s Progress with its Partnered Muscarinic Agonist Portfolio - GlobeNewswire
Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight - GlobeNewswire Inc.
Neurocrine Biosciences' SWOT analysis: stock outlook amid pipeline progress and market challenges - Investing.com
Neurocrine Biosciences explores new CAH treatments By Investing.com - Investing.com Canada
Neurocrine Bio stock overweight rating held on positive outlook By Investing.com - Investing.com Canada
Neurocrine Biosciences (NASDAQ:NBIX) Price Target Raised to $162.00 - MarketBeat
Neurocrine Biosciences explores new CAH treatments - Investing.com India
Neurocrine Biosciences (NBIX) Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism - StreetInsider.com
Neurocrine Biosciences Announces Publication on Traditional Glucocorticoid Treatment in Classic Congenital Adrenal Hyperplasia in Expert Review of Endocrinology & Metabolism - Longview News-Journal
Neurocrine Biosciences (NASDAQ:NBIX) shareholders have earned a 22% CAGR over the last three years - Simply Wall St
Neurocrine Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference - Kilgore News Herald
NBIXNeurocrine Biosciences Inc Latest Stock News & Market Updates - StockTitan
How to Take Advantage of moves in (NBIX) - Stock Traders Daily
Neurocrine Biosciences CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Neurocrine Biosciences executive sells $37,563 in stock By Investing.com - Investing.com Nigeria
Ingrid Delaet Sells 272 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Stock - MarketBeat
Neurocrine Biosciences executive sells $37,563 in stock - Investing.com India
Neurocrine Biosciences (NASDAQ:NBIX) Stock Passes Above 200-Day Moving AverageWhat's Next? - MarketBeat
Neurocrine Biosciences Announces Positive Top-Line Data from Phase 3 Study of Crinecerfont in Adults for the Treatment of Congenital Adrenal Hyperplasia - Marketscreener.com
Neurocrine Biosciences to Participate at Investor Conferences in December - cnhinews.com
Principal Financial Group Inc. Reduces Holdings in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences Stock Sees RS Rating Upgrade - Yahoo! Voices
NBIX: 3 Specialty Pharma Stocks Addressing Unmet Medical Needs - StockNews.com
Q1 EPS Forecast for Neurocrine Biosciences Lifted by Analyst - MarketBeat
Neurocrine Biosciences, Inc. Selects PANTHERx®Rare Specialty Pharmacy for Distribution of Crenessity™ (crinecerfont) - StreetInsider.com
Neurocrine Bio shares expected to grow with robust U.S. sales forecast for Crenessity - Investing.com UK
Neurocrine Biosciences (NASDAQ:NBIX) Receives "Overweight" Rating from Piper Sandler - MarketBeat
Barclays Increases Neurocrine Biosciences (NASDAQ:NBIX) Price Target to $165.00 - MarketBeat
Sanctuary Advisors LLC Buys 3,898 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX) - MarketBeat
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
BofA raises Neurocrine Bio target to $182 on drug launch By Investing.com - Investing.com Canada
What Analysts Are Saying About Neurocrine Biosciences Stock - Benzinga
Neurocrine Biosciences launches Crenessity in USA - The Pharma Letter
Needham & Company LLC Reiterates Hold Rating for Neurocrine Biosciences (NASDAQ:NBIX) - MarketBeat
Neurocrine launches CRENESSITY for adrenal hyperplasia in US By Investing.com - Investing.com South Africa
Neurocrine Bioscience’s CRENESSITY Becomes Commercially Available In The U.S. - Contract Pharma
Neurocrine Biosciences (NBIX) Announces Commercial Availability of CRENESSITY for Children and Adults With Classic Congenital Adrenal Hyperplasia - StreetInsider.com
Neurocrine launches CRENESSITY for adrenal hyperplasia in US - Investing.com
Neurocrine Biosciences Announces Commercial Availability of CRENESSITY™ (crinecerfont) for Children and Adults With Classic Congenital Adrenal Hyperplasia - PR Newswire
Finanzdaten der Neurocrine Biosciences Inc-Aktie (NBIX)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
0.08%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):